Scinovex
review Open AccessTop 1% cited

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

BMC Cancer · 2007 · Vol. 7(1) · pp. 153–153
Gustavo Arruda VianiSergio AfonsoEduardo Jose StefanoLígia Issa De FendiFrancisco V Soares

Abstract

The results from this meta-analysis are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC based on the risk: benefit ratio demonstrated in these studies. Adequate assessment of HER-2/neu status is critical, and careful cardiac monitoring is warranted because of cardiac toxicity. Clinical trials should be designed to answer unsolved questions.

HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAngiogenesis and VEGF in CancerTrastuzumabMedicineSurgical oncologyBreast cancerOncologyAdjuvantRandomized controlled trialMeta-analysisInternal medicineCancer

MeSH terms

TrastuzumabAntibodies, MonoclonalAntineoplastic AgentsBrain NeoplasmsBreast NeoplasmsFemaleGene AmplificationHeart DiseasesHumansRecurrenceGlobal HealthComorbidityCausalityIncidenceOdds Ratio
Citations
376
FWCI
12.61
field-weighted impact
References
33
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials · Scinovex